Literature DB >> 16750390

A yeast-based assay to isolate drugs active against mammalian prions.

Stéphane Bach1, Déborah Tribouillard, Nicolas Talarek, Nathalie Desban, Fabienne Gug, Hervé Galons, Marc Blondel.   

Abstract

Recently, we have developed a yeast-based (Saccharomyces cerevisiae) assay to isolate drugs active against mammalian prions. The initial assumption was that mechanisms controlling prion appearance and/or propagation could be conserved from yeast to human, as it is the case for most of the major cell biology regulatory mechanisms. Indeed, the vast majority of drugs we isolated as active against both [PSI(+)] and [URE3] budding yeast prions turned out to be also active against mammalian prion in three different mammalian cell-based assays. These results strongly argue in favor of common prion controlling mechanisms conserved in eukaryotes, thus validating our yeast-based assay and also the use of budding yeast to identify antiprion compounds and to study the prion world.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750390     DOI: 10.1016/j.ymeth.2006.04.005

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  18 in total

Review 1.  Antiprion drugs as chemical tools to uncover mechanisms of prion propagation.

Authors:  Déborah Tribouillard; Fabienne Gug; Hervé Galons; Stéphane Bach; Sven J Saupe; Marc Blondel
Journal:  Prion       Date:  2007-01-20       Impact factor: 3.931

Review 2.  Probing the role of structural features of mouse PrP in yeast by expression as Sup35-PrP fusions.

Authors:  Lyne Jossé; Ricardo Marchante; Jo Zenthon; Tobias von der Haar; Mick F Tuite
Journal:  Prion       Date:  2012-07-01       Impact factor: 3.931

3.  Prion 2016 Oral Abstracts.

Authors: 
Journal:  Prion       Date:  2016       Impact factor: 3.931

Review 4.  Modeling ALS and FTLD proteinopathies in yeast: an efficient approach for studying protein aggregation and toxicity.

Authors:  Dmitry Kryndushkin; Frank Shewmaker
Journal:  Prion       Date:  2011-10-01       Impact factor: 3.931

5.  A yeast-based assay identifies drugs active against human mitochondrial disorders.

Authors:  Elodie Couplan; Raeka S Aiyar; Roza Kucharczyk; Anna Kabala; Nahia Ezkurdia; Julien Gagneur; Robert P St Onge; Bénédicte Salin; Flavie Soubigou; Marie Le Cann; Lars M Steinmetz; Jean-Paul di Rago; Marc Blondel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-29       Impact factor: 11.205

6.  Yeast-based screening of natural product extracts results in the identification of prion inhibitors from a marine sponge.

Authors:  Laurence K Jennings; Ishtiaq Ahmed; Alan L Munn; Anthony R Carroll
Journal:  Prion       Date:  2018-09-13       Impact factor: 3.931

7.  Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.

Authors:  Nataša Obermajer; Julie Urban; Eva Wieckowski; Ravikumar Muthuswamy; Roshni Ravindranathan; David L Bartlett; Pawel Kalinski
Journal:  Nat Protoc       Date:  2018-01-18       Impact factor: 13.491

8.  Yeast prions form infectious amyloid inclusion bodies in bacteria.

Authors:  Alba Espargaró; Anna Villar-Piqué; Raimon Sabaté; Salvador Ventura
Journal:  Microb Cell Fact       Date:  2012-06-25       Impact factor: 5.328

9.  Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions.

Authors:  Déborah Tribouillard-Tanvier; Vincent Béringue; Nathalie Desban; Fabienne Gug; Stéphane Bach; Cécile Voisset; Hervé Galons; Hubert Laude; Didier Vilette; Marc Blondel
Journal:  PLoS One       Date:  2008-04-23       Impact factor: 3.240

10.  Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs.

Authors:  Déborah Tribouillard-Tanvier; Suzana Dos Reis; Fabienne Gug; Cécile Voisset; Vincent Béringue; Raimon Sabate; Ema Kikovska; Nicolas Talarek; Stéphane Bach; Chenhui Huang; Nathalie Desban; Sven J Saupe; Surachai Supattapone; Jean-Yves Thuret; Stéphane Chédin; Didier Vilette; Hervé Galons; Suparna Sanyal; Marc Blondel
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.